PRAX
Praxis Precision Medicines, Inc.
$257.25
-2.76%
$7.2B
No data for this timeframe.
Vol
Market Cap$7.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$5.3B
Inst. Activity28 buys / 12 sells
Reddit Sentiment50° Neutral
SEC Reports5
Press Releases4
Recent Activity
Jan 29, 2027
fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide.
Jun 11, 2026
SEC
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M increase, while two sel
INST-CLUSTER — Impact 4/10
Jun 10, 2026
Insider
Cudkowicz Merit Ester was granted 648 shares
Director
Jun 10, 2026
Insider
Norden Gregory was granted 1,371 shares
Director
Jun 10, 2026
Insider
YOUNG WILLIAM D was granted 648 shares
Director
Jun 2, 2026
Press
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem
Impact 1/10
May 7, 2026
SEC
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i
PRESS-RELEASE — Impact 8/10
May 4, 2026
SEC
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be published on May 7, 202
PRESS-RELEASE — Impact 2/10
Price Targets
$627.59
+144.0% upside
Strong Buy
Current $257.25
Low $162.00
Median $550.00
High $1,201.00
17 analysts
$162.00
$1,201.00
Analyst Ratings
9Strong Buy
11Buy
2Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Jun 2, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Jun 2, 2026 | Deutsche Bank | MAINTAIN | Buy → Buy |
| Jun 2, 2026 | Wedbush | MAINTAIN | Underperform → Underperform |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-3.71 ▲ +2.3% | $-5.33 — $-3.04 | -12% YoY | 14 |
| Next Q | $-4.05 ▼ -2.3% | $-6.46 — $-3.30 | -21% YoY | 14 |
| Current FY | $-15.27 | $-22.94 — $-13.25 | -13% YoY | 14 |
| Next FY | $-10.18 ▼ -18.6% | $-22.60 — $3.38 | 33% YoY | 13 |
Latest Reports
MIXED
INST-CLUSTER
4/10
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M increase, while two sel
Jun 11, 2026
NEUTRAL
Press
1/10
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem
Jun 2, 2026
BULLISH
PRESS-RELEASE
8/10
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $749.1M | — |
| FMR LLC | $696.2M | ADD |
| BAKER BROS. ADVISORS LP | $564.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $393.7M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Cudkowicz Merit | A | $0.00 |
| Jun 10, 2026 | Norden Gregory | A | $0.00 |
| Jun 10, 2026 | YOUNG WILLIAM | A | $0.00 |
| Jun 10, 2026 | Norden Gregory | A | $0.00 |
| Jun 10, 2026 | Chodakewitz Jeffrey | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $5.3B total value (16,303,648 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, FMR. Net buying activity: 28 institutions added/increased vs 12 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 2,324,929 | $749.1M | 14.3% | — |
| 3 | FMR LLC | 2,160,943 | $696.2M | 13.3% | ADD +59.0% |
| 4 | BAKER BROS. ADVISORS LP | 1,753,198 | $564.9M | 10.8% | ADD +55.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,221,944 | $393.7M | 7.5% | — |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 949,225 | $305.8M | 5.8% | ADD +86.4% |
| 7 | STATE STREET CORP | 884,238 | $284.9M | 5.4% | — |
| 8 | MORGAN STANLEY | 833,491 | $268.5M | 5.1% | ADD +38.3% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 815,739 | $262.8M | 5.0% | TRIM -59.3% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 756,748 | $243.8M | 4.6% | — |
| 11 | GOLDMAN SACHS GROUP INC | 710,734 | $229.0M | 4.4% | — |
| 12 | BANK OF AMERICA CORP /DE/ | 534,604 | $172.2M | 3.3% | — |
| 13 | RA CAPITAL MANAGEMENT, L.P. | 373,787 | $120.4M | 2.3% | NEW |
| 14 | Hood River Capital Management LLC | 358,618 | $115.5M | 2.2% | NEW |
| 15 | Pictet Asset Management Holding SA | 286,644 | $91.4M | 1.7% | NEW |
| 16 | FRANKLIN RESOURCES INC | 276,123 | $89.0M | 1.7% | — |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 215,447 | $69.4M | 1.3% | — |
| 18 | Woodline Partners LP | 200,013 | $64.4M | 1.2% | ADD +89.7% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 174,350 | $56.2M | 1.1% | DOUBLED +188.3% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 169,902 | $54.7M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 1,358,675 | 2,160,943 | +59.0% | $696.2M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | ADD | 1,126,488 | 1,753,198 | +55.6% | $564.9M | 2026-Q1 |
| Woodline Partners LP | ADD | 105,412 | 200,013 | +89.7% | $64.4M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEAR_EXIT | 3,240,086 | 84,947 | -97.4% | $27.4M | 2026-Q1 |
| MetLife Investment Management, LLC | DOUBLED | 12,424 | 80,930 | +551.4% | $26.1M | 2026-Q1 |
| Nuveen, LLC | ADD | 49,970 | 72,043 | +44.2% | $23.2M | 2026-Q1 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | NEW | — | 53,365 | — | $17.2M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 37,377 | 47,432 | +26.9% | $15.3M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 69,242 | 45,149 | -34.8% | $14.5M | 2026-Q1 |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | NEW | — | 42,163 | — | $13.6M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 69,712 | 40,130 | -42.4% | $12.9M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | TRIM | 88,704 | 33,335 | -62.4% | $10.7M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 22,715 | 31,220 | +37.4% | $10.1M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 23,543 | 31,161 | +32.4% | $10.0M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 14,862 | 30,510 | +105.3% | $9.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 15,796 | 29,525 | +86.9% | $9.5M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 13,655 | 28,134 | +106.0% | $9.1M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 22,240 | 15,188 | -31.7% | $4.9M | 2026-Q1 |
| Allianz Asset Management GmbH | DOUBLED | 2,400 | 14,030 | +484.6% | $4.5M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | DOUBLED | 1,732 | 8,536 | +392.8% | $2.7M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | DOUBLED | 3,316 | 7,388 | +122.8% | $2.4M | 2026-Q1 |
| Vestmark Advisory Solutions, Inc. | ADD | 4,505 | 6,681 | +48.3% | $2.2M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 552 | 5,060 | +816.7% | $1.6M | 2026-Q1 |
| GLENMEDE TRUST CO NA | TRIM | 6,288 | 3,410 | -45.8% | $1.1M | 2026-Q1 |
| XPONANCE LLC | ADD | 1,764 | 2,420 | +37.2% | $779.7K | 2026-Q1 |
13 unique insiders with 25 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Cudkowicz Merit Ester | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | Norden Gregory | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | YOUNG WILLIAM D | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | Norden Gregory | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | Chodakewitz Jeffrey | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | KINDLER JEFFREY B | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | YOUNG WILLIAM D | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | KINDLER JEFFREY B | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | MITCHELL DEAN J | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | MITCHELL DEAN J | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | Cudkowicz Merit Ester | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | Chodakewitz Jeffrey | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | DeSimone Jill | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | DeSimone Jill | Director | AWARD | 648 | — | — |
| Jun 10, 2026 | Arbuckle Stuart A | Director | AWARD | 1,371 | — | — |
| Jun 10, 2026 | Arbuckle Stuart A | Director | AWARD | 648 | — | — |
| May 14, 2026 | Souza Marcio | Chief Executive Officer | AWARD | 126 | $167.94 | $21.2K |
| May 14, 2026 | Sniecinski Megan | Chief Operating Officer | AWARD | 89 | $167.94 | $14.9K |
| May 14, 2026 | Kelly Timothy Edwin | Chief Financial Officer | AWARD | 121 | $167.94 | $20.3K |
| May 14, 2026 | Nemiroff Alex | General Counsel and Secretary | AWARD | 78 | $167.94 | $13.1K |
| May 14, 2026 | Mastrocola Lauren | Principal Accounting Officer | AWARD | 127 | $167.94 | $21.3K |
| Feb 6, 2026 | KINDLER JEFFREY B | Director | AWARD | 224 | — | — |
| Feb 6, 2026 | KINDLER JEFFREY B | Director | AWARD | 688 | — | — |
| Feb 6, 2026 | Arbuckle Stuart A | Director | AWARD | 224 | — | — |
| Feb 6, 2026 | Arbuckle Stuart A | Director | AWARD | 688 | — | — |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.6/10.
MIXED
INST-CLUSTER
4/10
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M inc
Jun 11, 2026
BULLISH
PRESS-RELEASE
8/10
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68
May 7, 2026
NEUTRAL
PRESS-RELEASE
2/10
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be pub
May 4, 2026
BULLISH
INST-CLUSTER
8/10
Six major institutional investors significantly increased or established new positions in Praxis Pre
Feb 28, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
NEUTRAL
1/10
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees un
Jun 2, 2026
BULLISH
8/10
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ul
Apr 14, 2026
BULLISH
8/10
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsun
Apr 6, 2026
BULLISH
8/10
Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class the
Mar 30, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 23 analysts: 9 strong buy, 11 buy, 2 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$627.59 mean target
+144.0% upside
Strong Buy (1.47)
$162.00 Low
$1,201.00 High
| Metric | Value |
|---|---|
| Current Price | $257.25 |
| Target Low | $162.00 |
| Target Mean | $627.59 |
| Target Median | $550.00 |
| Target High | $1,201.00 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.47) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-3.71 | $-5.33 | $-3.04 | -12.1% | +2.3% | 4↑ 8↓ | $0.0B | 0.0% | 14 |
| Next Q 2026-09-30 |
$-4.05 | $-6.46 | $-3.30 | -20.6% | -2.3% | 4↑ 8↓ | $0.0B | 0.0% | 14 |
| Current FY 2026-12-31 |
$-15.27 | $-22.94 | $-13.25 | -13.3% | -0.3% | 6↑ 8↓ | $0.0B | 0.0% | 14 |
| Next FY 2027-12-31 |
$-10.18 | $-22.60 | $3.38 | 33.3% | -18.6% | 5↑ 5↓ | $0.3B | 7402.2% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-3.711 | |
| 7d ago | $-3.694 | -0.017 |
| 30d ago | $-3.797 | +0.086 |
| 60d ago | $-3.794 | +0.083 |
| 90d ago | $-3.794 | +0.083 |
12 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jun 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 20, 2026 | BTIG | REITERATE | Buy | Buy |
| May 13, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| May 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 14, 2026 | Needham | REITERATE | Buy | Buy |
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 20, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Feb 20, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Feb 10, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Wells Fargo | INITIATE | — | Equal-Weight |
| Jan 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 12, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Dec 29, 2025 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| Apr 1, 2026 | 8 | 11 | 2 | 0 | 1 | 86% | |
| Mar 1, 2026 | 8 | 12 | 2 | 0 | 1 | 87% | |
| Feb 1, 2026 | 7 | 12 | 1 | 0 | 1 | 90% | |
| Jan 1, 2026 | 7 | 12 | 1 | 0 | 1 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jan 29, 2027
fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide. Indication: Essential Tremor. FDA accepted NDA fo
Sep 27, 2026
fda_pdufa
PDUFA: PRAX — relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies — 2026-09-27
FDA target action date 2026-09-27 for PRAX (Praxis Precision Medicines, Inc.). Drug: relutrigine. Indication: SCN2A and SCN8A developmental and epilep
Jun 4, 2026
other
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
<p align="left">BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_kcvXLmzZYfJ_cQTmaNQWB8pKLq2RGx7j3CKuK
Jun 2, 2026
activist
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervo
Jun 1, 2026
other
Praxis Precision Medicines Provides Vormatrigine Program Update
<p align="center"><em>POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure</em></p>
May 18, 2026
ftd
FTD: PRAX — 2,579 shares ($0.9M) failed to deliver
Settlement: 20260518, Price: $342.58, FTD Value: $883,513.82, PRAXIS PRECISION MEDICINES INC
May 13, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29
May 7, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
other
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervou
May 4, 2026
earnings
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
<p align="left">BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervou
Apr 30, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 14, 2026
fda
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
<p align="center"><em>FDA assigned PDUFA target action date of January 29, 2027</em></p>
Apr 6, 2026
fda
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
<p align="center"><em>Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015)</em></p>
Apr 2, 2026
other
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nerv